# Mario Campone

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mario-campone/

## Facts

| Field | Value |
| --- | --- |
| Citations | 53,975 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 94 |
| i10-index | 394 |
| Last Known Institution | Institut de Cancérologie de l'Ouest |
| OpenAlex ID | https://openalex.org/A5071553983 |
| ORCID iD | https://orcid.org/0000-0002-5196-5908 |
| Works | 1,090 |

## Researcher papers

- [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://scholariq.org/papers/ribociclib-as-first-line-therapy-for-hr-positive-advanced-breast-cancer/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer](https://scholariq.org/papers/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus/)
- [Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034](https://scholariq.org/papers/randomized-phase-ii-trial-of-erlotinib-versus-temozolomide-or-carmustine-in/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)
- [Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study](https://scholariq.org/papers/evaluation-of-bgj398-a-fibroblast-growth-factor-receptor-1-3-kinase-inhibitor-in/)
- [Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study](https://scholariq.org/papers/adjuvant-abemaciclib-combined-with-endocrine-therapy-for-high-risk-early-breast/)
- [Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods](https://scholariq.org/papers/prognostic-value-of-o6-methylguanine-dna-methyltransferase-status-in/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Institut de Cancérologie de l'Ouest](https://scholariq.org/institutions/institut-de-cancerologie-de-l-ouest/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.